← Eichor
Study identifier: NCT06066710 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Propranolol in Primary Progressive Aphasia

Condition: Aphasia, Primary Progressive  ·  Sponsor: University of Missouri-Columbia

PhaseEARLY_Phase 1
Planned participants30
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure. This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.

This description comes directly from the study's public registry record.

Talk to the study team

David Beversdorf, MD  ·  573-882-6081  ·  beversdorfd@health.missouri.edu

Kim Ray  ·  573-882-0515  ·  raykk@health.missouri.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Missouri-ColumbiaColumbia, Missouri, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06066710